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Summary:   
Background:  Metformin might reduce insulin requirement and improve glycaemia in patients 
with type 1 diabetes, but whether it has cardiovascular benefits is unknown.  We aimed to 
investigate whether metformin treatment (added to titrated insulin therapy) reduced 
atherosclerosis, as measured by progression of common carotid artery intima-media thickness 
(cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease.  
Methods  REMOVAL was  a double-blind, placebo-controlled trial undertaken at 23 hospital 
diabetes clinics in five countries (Australia, Canada, Denmark, the Netherlands, and the UK). 
Adults aged 40 years and older with type 1 diabetes of at least 5 years’ duration and at least 
three of ten specific cardiovascular risk factors were randomly assigned (via an interactive 
voice response system) to oral metformin 1000 mg twice daily or placebo.  Participants and site 
staff were masked to treatment allocation. The primary outcome was averaged mean far wall 
cIMT, quantified annually for 3 years, analysed in a modified intention-to-treat population (all 
randomly assigned participants with post-randomisation data available for the outcome of 
interest at any given timepoint, irrespective of subsequent adherence or study participation), 
using repeated measures regression.  Secondary outcomes were HbA1c, LDL cholesterol, 
estimated glomerular filtration rate (eGFR), incident microalbuminuria (not reported), incident 
retinopathy, bodyweight, insulin dose, and endothelial function, also analysed in all participants 
with post-randomisation data available for the outcome of interest at any given timepoint.  This 
trial is registered with ClinicalTrials.gov, number NCT01483560.  
Findings:  Between Dec 14 2011, and June 24, 2014, 493 participants entered a 3 month run-in 
to optimise risk factor and glycaemic control (single-blind placebo in the final month). Of 428 
randomly assigned patients, 219 were allocated to metformin and 209 to placebo.  Progression 
of mean cIMT was not significantly reduced with metformin (-0·005 mm per year, 95% CI -
0·012 to 0·002; p=0·1664), although maximal cIMT (a prespecified tertiary outcome) was 
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significantly reduced (-0.013 mm per year, -0.024 to -0.003; p=0.0093).  HbA1c  (mean 8.1% 
[SD 0.9] for metformin and 8.0% [0.8] for placebo at baseline) was reduced on average over 3 
years by metformin (-0.13%, 95% CI -0.22 to -0.037; p=0.0060), but this was accounted for by 
a reduction at the 3-month timepoint (-0.24%, -0.34 to -013; p<0-0001) that was not sustained 
thereafter (p=0.0163 for visit-by-treatment interaction).  Bodyweight (-1·17 kg, 95% CI -1·66 
to -0·69; p<0·0001) and LDL cholesterol (-0·13 mmol/L,, -0·24 to -0·03; p=0·0117)  were 
reduced with metformin over 3 years of treatment, and eGFR was increased (4·0 mL/min per 
1.73m
2
, 95% CI 2.19 to 5.82; p<0·0001).  Insulin requirement was not reduced on average over 
3 years (-0.005 units per kg, 95% CI -0.022 to 0.012; p=0.545), but there was a significant 
visit-by-treatment interaction (p=0.0018).  There was no effect on endothelial function as 
measured by reactive hyperaemia index, or on retinopathy.   Discontinuation of treatment in 59 
(27%) participants on metformin versus 26 (12%) on placebo (p=0·0002) was mainly due to an 
excess of gastrointestinal adverse effects, and there was no increase in hypoglycaemia with 
metformin. Five deaths occurred among patients allocated to metformin and two occurred 
among those allocated to placebo; none were judged by site principal investigators to be related 
to study medication.  
Interpretation:  These data do not support use of metformin to improve glycaemic control in 
adults with long-standing type 1 diabetes as suggested by current guidelines, but suggest that it 
might have a wider role in cardiovascular risk management.  
Funding: JDRF. 
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Introduction 
 
Cardiovascular disease (CVD) is a major cause of reduced life expectancy in type 1 diabetes  
and CVD is more than twice as common as in the background population.
1,2
  Results from the 
Diabetes Control and Complications Trial (DCCT) and its post-randomisation follow-up study 
(Epidemiology of Diabetes and its Complications [EDIC]) showed that intensive glucose 
control in T1D reduces the onset and progression of microvascular and cardiovascular 
complications.
3
   However, in most countries more than 30% of adults with type 1 diabetes 
have poor glycaemic control;
4
 furthermore, many patients are overweight or obese,
5
 and, on the 
basis of data from Scotland,  more than 60% of patients aged 40-59 years have poorly-
controlled cholesterol.
1
  
US and UK guidelines recommend adding metformin, an inexpensive therapy, to insulin in 
overweight or obese individuals with type 1 diabetes to improve blood glucose control and 
reduce insulin dose requirement.
6,7
 This advice is based partly on findings from our meta-
analysis of short-term and heterogeneous studies in which metformin was shown to reduce 
insulin requirement with possible benefits on weight and HbA1c.
8
  However, metformin is not 
widely used for this off-label indication; the 2015 UK guideline called for more research.
6 
 In 
Scotland, about 15% of adults with type 1 diabetes have ever received metformin, with a 
typical prevalent use of about 8% (unpublished analysis of 2016 national data).  
Because metformin reduces risk of CVD in type 2 diabetes,
9,10
 we hypothesised that it might 
also have important cardiovascular as well as metabolic effects in type 1 diabetes.  Progression 
of common carotid artery intima-media thickness (cIMT ) is a surrogate of atherosclerosis
11,12
 
that predicts future CVD events in the general population.
13
  Progression of cIMT was reduced 
in DCCT participants who were previously allocated to 6.5 years previous intensive glucose 
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control in the first 6 years of EDIC follow-up and was associated with reduced CVD events 30 
years from original randomisation.
3,14
  
 
We therefore initiated the REMOVAL study (REducing with MetfOrmin Vascular Adverse 
Lesions), an international double-blind, randomised, placebo-controlled trial with the primary 
aim of testing whether 3 years of treatment with metformin 1000 mg twice daily added to 
titrated insulin therapy (towards target HbA1c 7·0% [53 mmol/mol]) reduces atherosclerosis, as 
measured by progression of cIMT, in adults with confirmed type 1 diabetes aged 40 years and 
older and at increased risk for CVD.
15
   
 
Methods  
Study design and participants 
The design of REMOVAL, an international randomised, parallel group trial of metformin 
versus placebo in adults with type 1 diabetes, has been described previously.
15
 The study was 
done in 23 hospital diabetes clinics in  Australia, Canada, Denmark, the Netherlands and the 
UK (17 initial sites plus six additional UK sites added in 2012 to meet recruitment targets).  
The protocol (appendix) was approved by the West of Scotland Research Ethics Service and 
relevant committees covering all sites.
15
 The University of Glasgow (Glasgow, UK) and NHS 
Greater Glasgow and Clyde (Glasgow, UK) were co-sponsors and specific responsibilities were 
delegated to international partner institutions. All participants provided written informed 
consent.   
Individuals aged 40 years or older with type 1 diabetes of at least 5 years’ duration and at least 
three of the following ten specified CVD risk factors were eligible: BMI ≥ 27 kg/m2; current 
HbA1c>8·0% (64 mmol/mol) established CVD; strong family history of CVD (defined as at 
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least one parent, biological aunt or uncle, or sibling with myocardial infarction or stroke aged 
<60 years); current smoker; microalbuminuria (defined according to routine care screening 
systems at sites); estimated glomerular filtration rate (eGFR) <90 ml/min per1.73m
2
; 
hypertension (blood pressure ≥140/ 90 mmHg or  established antihypertensive treatment); 
dyslipidaemia [total cholesterol ≥5·0 mmol/L;  HDL cholesterol <1·2 mmol/L [men] or <1·3 
mmol/L [women],  triglycerides ≥1·7 mmol/L; or established  lipid-lowering treatment); and 
diabetes duration >20 years (details in appendix p 7).  Type 1 diabetes was defined in the initial 
protocol (version 1.0; June 23, 2011) as diagnosis of diabetes before age 35 years and insulin 
use within 1 year; the upper limit for age of diagnosis was revised to 40 years in protocol 
version  2.0 ( September 2012) following review of screening logs (the requirement of type 1 
diabetes duration of at least 5 years was retained). 
Randomisation and masking  
Following a 3 month run-in period with placebo masked to participants in the final month, 
participants who remained eligible (≥70% medication adherence and random C-peptide ≤ 0·2 
nmol/L at enrolment) were randomly assigned to receive metformin or placebo for 3 years. The 
placebo and active drug were identical in formulation (including excipients) and matched in 
shape and colour.  Follow-up was abbreviated by between 1 and 8 months for the final 50 
participants, in accordance with the final protocol (version 3.0; Nov 9,  2015).  After 
confirming entry criteria, randomisation was achieved via an interactive voice response system 
hosted by the study data centre at the Robertson Centre of Biostatistics (Glasgow Clinical 
Trials Unit), University of Glasgow, Glasgow, UK.  The randomisation list was generated by 
use of a pseudo random number generator.  Randomisation was stratified by study site, based 
on randomly permuted blocks allocated within each trial centre.   Staff who generated the 
randomisation sequence had no role in any other part of the trial.   Participants and site staff 
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were fully masked to group assignment and all analyses predefined in the statistical analysis 
plan were programmed masked to treatment allocation.   
Procedures   
During the run-in period CVD risk factor management was optimised in accordance with local 
guidelines at sites and insulin regimens were reviewed with the aim of optimising glycaemic 
control (target HbA1c 7·0% [53 mmol/mol]) with additional clinic visits if necessary.  A 
randomisation visit (fasting) was then scheduled for baseline assessments including cIMT, 
endothelial function and non-mydriatic colour retinal digital photographs.  Study medication 
was either oral metformin hydrochloride 1000 mg twice daily with food (as Glucophage 500 
mg) or placebo, provided free of charge by Merck KGaA (Darmstadt, Germany), and dispensed 
in identical packages with sufficient supply for 3 or 6 months, dependent on the visit schedule.  
Participants were given instructions on up-titrating study medication on a weekly basis from 
one tablet daily to two tablets twice daily (with meals) in week 4, with support from telephone 
visits.  Lower doses were permitted for participants if adverse events occurred on higher doses.  
Adjustments in insulin doses towards target HbA1c were made at the discretion of site staff 
rather than being specified by the protocol.  Study visits were scheduled to coincide with 
routine care appointments when possible; main study outcomes were reassessed at 12, 24 and 
36 months.  Participants continued to have access to usual local arrangements for diet, lifestyle 
and weight management throughout the trial; ongoing management of glycaemia, blood 
pressure and lipids was under the care of the site principal investigator and usual care team.  A 
glycaemia committee sent detailed reports (masked to treatment allocation) on participants’ 
HbA1c and rates of hypoglycaemia to each site every 6 months along with benchmarking data 
from other sites in their region.   
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Outcomes  
The primary outcome was progression of averaged mean far wall cIMT (measured in mm, at 
baseline, 12, 24 and 36 months).  Right and left common carotid arteries were interrogated by 
B-mode ultrasound with a 7.0 MHz or higher broadband linear array transducer, with 
concurrent recording of three lead electrocardiograph. Longitudinal images were obtained at 
anterior, lateral and posterior angles using Meijer’s arc during at least five cardiac cycles.  
Centres were asked to submit six duplicate sets of scans for each annual study visit for 
assessment of quality control.  The concordance correlation coefficient (CCC) for averaged 
mean far wall cIMT was 0·968 overall (ranging between 0·953 and0·979 by visit). At the 
reading centre (University College London, London UK), measurements were taken from the 
distal centimetre of the common carotid artery (i.e. immediately proximal to the bulb) by a 
single trained assessor using a validated semi-automated programme.  Repeat quality control 
cycles for the assessor yielded an overall CCC of 0·946 (ranging between 0·918 and 0·968).  
Individual measures of mean cIMT of greater than 1·5 mm, indicative of plaque, at any 
timepoint during follow-up were excluded from the primary outcome analysis, as 
recommended by the Mannheim Consensus.
16
   
Secondary outcomes
15
 were: HbA1c measured by local laboratories using DCCT-standardised 
assays;  LDL cholesterol (measured centrally at the University of Glasgow);  eGFR calculated 
on the basis of  serum creatinine measured by local laboratories by use of the Modification of 
Diet in Renal Disease Study equation;  incident microalbuminuria among individuals who had 
normalbuminuria at baseline (on the basis of clinical history plus urine collection; this 
measurement was augmented by collection and storage of urine aliquots for later central 
analysis if indicated); the data for which are not reported in this paper for reasons stated in 
Results; incident retinopathy, defined as two or more step progression (concatenated) read from 
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two colour 45° field photographs (field 1, optic disc; field 2, macula) taken from each eye at 
randomisation and at 36 months (graded with custom-designed software at the University of 
Wisconsin-Madison Ocular Epidemiology Reading Center [Madison, WI, USA] by  use of  the 
modified Airlie House classification scheme and the 11-step modified Early Treatment 
Diabetic Retinopathy Study [ETDRS] severity scale);
 
 bodyweight in kg (by calibrated scales); 
insulin dose (in units per kg); and endothelial function assessed at 0, 12 and 36 months as 
reactive hyperaemia index (RHI) in some study centres (14 centres provided data for 
endothelial function, covering 80% of participants)  and read by staff masked to treatment 
status (EndoPAT, Itamar Medical, Caesarea, Israel). Improvement in two or more of the 
secondary outcomes was prespecified as clinically meaningful with the potential to influence 
clinical practice in the event of a positive primary outcome.  
Tertiary outcomes were: frequency of hypoglycaemia assessed using the modified Steno 
Hypoglycaemia Questionnaire, in which events were classified as minor (self-treated, resolved 
with short acting glucose and longer-acting carbohydrate) or major (requiring assistance from 
another person; treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire); 
biochemical markers of endothelial function (tissue plasminogen activator, sE-selectin, and 
sICAM-1), the data for which are not reported in this paper for reasons stated in the Results; 
progression of averaged maximal far wall cIMT (in which plaque was included as 
recommended);
14,17,18 
and  Vitamin B12 status as measured by local laboratories. 
For assessment of safety, data for incident diabetes-related complications, operations, or 
procedures and adverse events of medical significance (gastrointestinal, metabolic, and renal) 
that were not captured as outcomes were collected at each visit.  Dose reduction of study 
medication was recommended per protocol if eGFR fell below 45 mL/min per 1.73m
2 during 
follow-up.  Specific thresholds for permanent discontinuation of study medication were 
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stipulated by monitoring of biomarkers (alanine transaminase >3·0 times upper limit of normal; 
eGFR <30 mL/min per 1.73m
2
; or serum lactate >5·0 mmol/L with acidosis or >3·0 mmol/L if 
confirmed by a mandated second measurement within 1 week).  Participants whose Vitamin 
B12 concentrations fell below 150 pmol/L were offered the choice of treatment discontinuation 
or referral for supplementation.  All serious adverse events were collected and reported 
according to standard operating procedures. 
Statistical analysis 
Data management and statistical analyses were done at the study data centre (Robertson Centre 
for Biostatistics, University of Glasgow, Glasgow, UK).
15
 The study was designed, assuming 
mean cIMT progression of 0.044 mm over 3 years in the control group, to provide 90% power 
to detect a mean difference of 0·0167 mm (a third of an SD, assumed to be 0·05) in change 
from baseline of averaged mean far-wall cIMT between treatment groups (=0·05), assuming 
enrolment of 500 participants and 20% loss to withdrawal or discontinuation of treatment. 
Analysis of the primary outcome was based on a repeated-measures random regression model 
assuming a general residual covariance structure with random intercepts and slopes, adjusted 
for baseline cIMT as well as for age, sex, smoking status, systolic blood pressure, BMI, HbA1c 
and LDL cholesterol, and was therefore expected to provide additional power.  Regression 
model effect estimates with 95% CIs and associated p-values were calculated.  The same 
approach was used for analysis of the tertiary cIMT outcome.   For the primary outcome, 
prespecified sensitivity analyses were done as follows: to account for differences in ultrasound 
machines used at sites by adjusting for ultrasound probe frequency, based on a per-protocol 
analysis; and with multiple imputation of missing cIMT values. Analyses were done on a 
modified intention-to-treat basis, including all randomly assigned participants with post-
randomisation data available for the outcome of interest at any given timepoint, irrespective   of 
subsequent participation in the study or ongoing adherence to study medication.   
 11 
 The sample size also provided 90% power to detect changes from baseline in secondary 
outcomes of HBA1c,  LDL cholesterol, eGFR, bodyweight, insulin dose and endothelial 
function of about 0·3 SD (α=0·05). The retinopathy secondary outcome was likely to be 
underpowered because a 60% reduction in 3 year two-step or greater progression in the ETDRS 
severity scale was required to achieve 80% power.  Outcomes were analysed as follows: 
ANCOVA, for change from baseline for continuous secondary and tertiary outcomes (HbA1c, 
LDL cholesterol, eGFR, bodyweight, insulin dose, endothelial function, and treatment 
satisfaction); Cox proportional-hazards for occurrence of vitamin B12 concentration of less 
than 150 pmol/L (tertiary outcome); negative binomial regression models for rates of 
hypoglycaemia (tertiary outcome); and logistic regression analysis for two or more step 
progression of retinopathy (secondary outcome).  The ANCOVA analyses were further 
extended, as prespecified, to include a visit-by-treatment interaction term to investigate whether 
the treatment effect varied over time.  In the event of a significant interaction being found, the 
nature of the interaction was explored by plotting treatment effects over time.  Comparisons 
between groups for the permanent discontinuations from study medication and the number of 
individuals who had at least one serious adverse event were made with χ2 tests.  Analyses were 
done with SAS (version 9.3). No adjustments for multiple comparisons were prespecified. 
  No interim efficacy analyses were planned.  An independent data monitoring committee 
reviewed unmasked reports on study progress every 6 months to monitor patient safety, the 
quality of efficacy information, and study conduct, as well as providing a recommendation to 
the sponsor on the appropriateness of continuing the study to completion. 
 This trial is registered with ClinicalTtrials.gov, number  NCT01483560. 
Role of the funding source  
During planning of the study, the funder (JDRF) hosted workshops to discuss principles of trial 
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design for adjunctive therapy in type 1 diabetes and to encourage funding applications; 
however, the funder had no role in data collection, data analysis, data interpretation, or writing 
of the report.  Merck KGaA (which donated study medication) had no role in study design, data 
collection, data analysis, data interpretation, but a representative was offered the opportunity to 
comment on the report before submission. The corresponding author and trial steering 
committee (appendix p 2) had full access to all study data and provided regular progress reports 
to the funder and pharmacovigilance reports to Merck KGaA.  The corresponding author and 
trial steering committee had final responsibility for the decision to submit for publication. 
 
Results  
Between Dec 14, 2011, and June 24, 2014, 493 participants with type 1 diabetes were enrolled 
in a 3 month run-in with single-masked placebo in the final month.  428 individuals were 
subsequently randomly assigned, with 219 allocated to metformin and 209 to placebo (figure 
1).  Final data collection was on March 19, 2017.  The characteristics of the treatment groups at 
randomisation were well balanced, and reflected the entry criteria requirement of at least three 
CVD risks factors. Across treatment groups, mean age was 55
.
5 years (SD 8
.
6), diabetes 
duration was 33
.
8 years (10.8), BMI was 28·5 kg/m
2 
(4
.
3); and HbA1cwas 8
.
05% (0·82; 64·5 
mmol/mol [9
.
00]; table 1). 34% (145 of 428) of patients used insulin pump therapy; mean 
systolic and diastolic blood pressure were 129
.
5 mm Hg (SD 14
.
8) and 72
.
3 mmHg (10
.
1), 
respectively with 73% [313 of 428] on antihypertensive medication), and LDL cholesterol was 
2·2 mmol/L (0
.
71; with 82% [349 of 428] on a statin; table 1).   
 The difference in mean within-person cIMT slopes (metformin relative to placebo) for the 
primary outcome (modified intention-to-treat analysis) was -0·005 mm per year (95% CI -
0·012 to 0·002, p=0·167); table 2, figure 2).  There was no treatment-by-sex interaction (data 
not shown).   
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 Of the secondary outcomes (table 3, figure 3), HBA1c was reduced by metformin over 3 years 
(-0.13%, 95% CI -0.22 to -0.04; p=0.0060), but this was accounted for by a reduction at the 3-
month timepoint (-0·24%, -0·34 to -0·13; p<0·0001) that was not sustained thereafter 
(p=0·0163 for visit-by-treatment interaction). There was no reduction in insulin dose 
requirement on average over 3 years (-0.005 units per kg, 95% CI -0.022 to 0.012; p=0.5450), 
but there was evidence of a significant interaction between treatment and visit (units per kg; 
p=0·0018), with little difference between the treatment groups in the 6 months, followed 
thereafter by a small  but sustained reduction in patients allocated to metformin (estimated in 
post-hoc analyses as -0.023 units per kg, 95% CI -0.045 to -0.0005; p=0.045; figure 3).  
Differences favouring metformin were recorded in the mean within-person change between 
treatment groups in bodyweight (-1.17 kg, 95% CI -1·66 to-0·69; p<0·0001 and LDL 
cholesterol (-0·13 mmol/L,-0·24 to -0·03); p=0·0117); these changes would have met the 
secondary composite outcome (at least two of the secondary outcomes showing significant 
improvement) had the primary outcome shown a significant difference.  There was also a 
significant increase in eGFR with metformin [4·00 mL/min per1.73m
2
 (95% CI 2·19 to 5·81; 
p<0·0001; table 3, figure 3). There was no evidence of a treatment effect on endothelial 
function (as measured by RHI) or on retinopathy (table 3).  We did not have adequate data for 
analysis of incident microalbuminuria at the time was prepared because medical history 
information was not well captured for patients with eGFR of less than90 mL/min per 1.73m
2
, 
insufficient local laboratory biochemical data were available reliably to ascertain 
microalbuminuria status in accordance with the protocol definition, and central analysis of 
stored urine aliquots had not yet been done. 
The tertiary cIMT outcome (averaged maximal) showed an increase over time in both treatment 
groups (table 2, figure 2) with reduced progression in association with metformin (difference in 
slope –0·013 mm per year, (95% CI -0·024 to -0·003; p=0·0093; Figure 2, table 2).  There was 
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no difference between groups for minor or major hypoglycaemia, and no change in treatment 
satisfaction (table 4).  Biochemical markers of endothelial function had not been measured at 
the time this report was prepared.  
59 (27%) participants on metformin and 26 (12%) on placebo discontinued treatment during 
the trial (table 4; (p=0.0002; (Kaplan-Meier plot in appendix [p 9]).  Discontinuation was due 
to gastrointestinal adverse effects in 34 (16%) participants on metformin and seven (3%) on 
placebo.  The number of individuals who had at least one serious adverse event was similar 
between groups (34 [16%] patients on metformin vs 31 [15%] patients on placebo; p=0·8418; 
appendix p 8).  
Biochemical Vitamin B12 deficiency (<150 pmol/L) was more frequent with metformin (table 
4). Therapy was discontinued because of asymptomatic hyperlactataemia in four individuals on 
metformin and none on placebo; there were no cases of lactic acidosis.  Five deaths occurred 
among patients allocated to metformin (three from cancer, two from cardiac disease) and two 
occurred among those allocated to placebo (one from cancer, one from cardiac disease; table 
4); none were judged by site principal investigators to be related to study medication.   No 
changes in blood pressure control were seen with metformin therapy (data not shown). 
 
Discussion  
 
Adding metformin to insulin therapy and standard of care for 3 years in adults with 
longstanding type 1 diabetes and high cardiovascular risk did not significantly alter 
atherosclerosis progression as measured by the primary outcome (averaged mean cIMT) and 
did not have a sustained effect on glycaemic control.  However, we did identify reductions in 
bodyweight, LDL cholesterol, and insulin dose requirement per unit of bodyweight, and a 
reduction in atherosclerosis progression as measured by the prespecified tertiary outcome of 
 15 
averaged maximal cIMT.  Metformin was poorly tolerated by a substantial minority of 
participants, mainly because of gastrointestinal upset.  
Before REMOVAL, the longest trial of metformin versus placebo in patients with type 1 
diabetes was for 1 year in 100 individuals at the Steno Diabetes Center.
19
  Our systematic 
review of nine metformin trials in type 1 diabetes (192.8 patient-years) provided some evidence 
for a reduction in insulin dose requirement (estimated at 6·6 units per day) when metformin 
was added to insulin.
8
  Bodyweight reduction was reported in three of six studies and HbA1c 
reduction in four of seven studies, but heterogeneous data for these outcomes could not be 
combined to give a pooled estimate of effect size.
8
  
In a recent trial by the US T1D Exchange group, 140 adolescents, over half of whom met 
criteria for obesity, were randomly assigned to metformin or placebo for 6 months.  Metformin 
reduced bodyweight and caused a transient reduction in HbA1c at 13 weeks (-0·3%) which 
reverted to baseline by 26 weeks, with a mean reduction in insulin dose requirement with 
metformin of 0·1 unit per kg (about 8 units per day) at both 13 and 26 weeks.20  This reduction 
was similar to the 6.6 units per day noted in our systematic review,
8
 but about four times higher 
than seen during years 2 and 3 of REMOVAL (0.023 units per kg or about 1.9 units per day). 
This difference in findings might have been because baseline doses were almost twice as high 
in the T1D Exchange trial (1·1 vs 0·63-0
.
68 units per kg); notably, in the T1D Exchange trial, 
the difference was also detected earlier at 3 months rather than 6 months.   
The only trial of metformin in type 1 diabetes previously to have reported a reduction in LDL 
cholesterol (by 0·3 mmol/L) was the trial done at the Steno Diabetes Center, 
21
 in which a much 
lower proportion of participants was treated with statins than in REMOVAL (about 37% vs 
82%) with a substantial imbalance at baseline favouring the metformin group.  In REMOVAL, 
statin use was well balanced at baseline between groups. Although the effect size in 
REMOVAL was similarly small, it is likely to have been attenuated by treatment of LDL 
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cholesterol to target in both groups according to local guidelines. Despite the fairly small effect 
size, if this reduction in LDL cholesterol was sustained over decades (rather than the 3 years of 
the trial), it could have an effect on CVD outcomes in patients with type 1 diabetes.  Although 
this effect could have been achieved by other means, from a global perspective it is relevant 
that generic metformin has a low acquisition cost.  
Metformin is associated with cardiovascular benefit in type 2 diabetes.
9,10
 These effects are not 
necessarily mediated by glucose lowering- e.g. inhibition of STAT3 (and thereby monocyte-to-
macrophage differentiation) via activation of AMPK in vascular tissues has been implicated in 
a direct anti-atherosclerotic action of metformin.
22
  Moreover, metformin can improve aspects 
of endothelial function 
23
 and inhibit formation of advanced glycation end products  by binding 
and inactivating methyglyoxal via an AMPK-independent pathway.
24
   
Previous evidence that metformin can reduce atherosclerosis progression as measured by cIMT 
is inconsistent and based on underpowered, unblinded studies. Results of a double-blind, 
placebo-controlled trial in people without diabetes but with CVD showed no effect of 
metformin on mean cIMT.
25
  However, the mechanisms of atherosclerosis progression in type 1 
diabetes may differ from those in other conditions. 
By design, participants in REMOVAL had increased CVD risk and about 12% had established 
CVD.   However, progression of the primary outcome (averaged mean cIMT) in the placebo 
group was only about two-thirds of that predicted (0·030 vs 0·044 mm), perhaps because of 
high levels of risk-factor management with statins and anti-hypertensive agents.  By  contrast, 
progression of the tertiary outcome, averaged maximum cIMT, was higher than in younger 
DCCT/EDIC participants, as was the reduction in cIMT progression with metformin (-0·039 
mm over 3 years in REMOVAL vs -0·013 to -0·019 mm over 5 years in DCCT-EDIC).
14,26
 Our 
selection of mean cIMT, which excludes individual readings greater than 1·5 mm and plaque, 
as a primary outcome was driven by the aimed of reducing variability in accordance with 
 17 
recommendations from the Mannheim Consensus,
16
 although there is evidence of improved 
risk prediction with our tertiary outcome maximal cIMT, which might be more reflective of 
atherosclerosis progression than mean cIMT because it includes more advanced stages of 
disease, including focal thickening or plaque.
26
 
During DCCT and the early EDIC study, use of statins and antihypertensive agents was 
uncommon in people with type 1 diabetes.  Reduction in maximal cIMT in EDIC following 
previous intensive glucose control was later followed by a 30% reduction in CVD events over a 
total follow-up period of 30 years.
3
 It is premature to conclude that the effect of metformin on 
maximal cIMT in REMOVAL might translate to such substantial effects on clinical outcomes; 
especially in view of its status as a tertiary outcome.  Notably, the contribution of reduced 
cIMT progression per se to lowered CVD outcome rates independent of glycaemia has not been 
formally explored in DCCT/EDIC.  Conversely, although cIMT is simply a surrogate endpoint 
for downstream CVD events, the concordance in findings between trials that use cIMT 
progression and CVD outcomes is excellent, with a positive predictive value of 96%.
11
  
Our findings suggest that metformin might have direct effects on atherosclerosis progression in 
patients with type 1 diabetes, even in middle-aged individuals with long diabetes duration who 
are well treated with antihypertensive drugs and statins. In view of the absence of a persistent 
effect of metformin on HbA1c, this possible effect is unlikely to have been mediated by 
improved glycaemic control.  Although an effect of metformin on endothelial function in 
conduit arteries has been reported in a double-masked, randomised placebo-controlled pilot 
trial (n=42),
27
 we identified  no effect in small resistance arteries using  RHI in what was one of 
the largest studies of vascular function in type 1 diabetes to date. 
Although evidence from the DCCT/EDIC implicates hyperglycaemia as the key driver of 
atherosclerosis and CVD in type 1 diabetes, renal disease also has an important role.
3
  In 
REMOVAL, mean eGFR fell by 4 mL/min per 1.73m
2
 over 3 years in the placebo group, as 
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expected in this population.  However, in the metformin group, it rose acutely within the first 
month and then followed a parallel trajectory to placebo until the end of the trial, at which point 
separation was maintained; eGFR was a prespecified secondary outcome, but this was an 
unexpected finding that we believe should not be overemphasised at this stage.  We cannot 
assess whether decline in renal function was stabilised by metformin because eGFR was not 
remeasured after study medication was discontinued.  Since metformin and creatinine share 
renal proximal tubule transport mechanisms,
28
 we speculate that metformin might acutely 
increase tubular excretion of creatinine, affecting its validity as a biomarker of renal function, 
although this phenomenon has not previously been described in metformin’s 60 year history.  
Together with other recent data,
29
 these findings warrant further investigation. 
As the largest and longest clinical trial of metformin treatment in patients with type 1 diabetes 
to date, REMOVAL provides valuable information about its tolerability and safety.  Around a 
quarter of individuals (twice as many as in the placebo group) discontinued metformin over 3 
years, suggesting that about one in eight had genuine intolerance, with the excess being 
attributable to gastrointestinal adverse effects.  Although this finding potentially limits wider 
use of metformin in unselected individuals with type 1 diabetes, such intolerance is usually 
evident in the early months of use; additionally, prolonged release metformin is available and 
has fewer gastrointestinal side-effects.
30
 
 In terms of safety, the risk of biochemical vitamin B12 deficiency was more than doubled over 
3 years on metformin (12%) versus placebo (5%). Because vitamin V12 concentrations are not 
usually monitored in current practice, undetected clinically significant deficiency could develop 
over time, potentially contributing to sensory neuropathy in individuals already at risk.  Our 
findings contribute to growing  evidence that treatment with metformin reduces vitamin B12 
concentrations, suggesting that levels should be monitored during long-term use,
7,,31,32
 
particularly in type 1 diabetes, in which there is associated risk of gastroparesis, pernicious 
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anaemia, and coeliac disease.  We noted several cases of asymptomatic hyperlactataemia in 
patients treated with metformin and none in the placebo group however, there were no cases of 
lactic acidosis and the clinical significance of this finding is uncertain.  
Limitations of the REMOVAL trial include use of an intermediate primary CVD outcome 
rather than a clinical one.  Notably, no previous randomised trial of any intervention in type 1 
diabetes has had a CVD primary outcome; despite the undoubted relevance of CVD in type 1 
diabetes, REMOVAL is the first to include even a surrogate measure.  The study was powered 
on the assumption that the SD of change from baseline for mean cIMT was 0.05 but despite 
central reading and an ongoing quality assurance programme, the observed value was 0
.
09. 
Although additional power is likely to have been achieved because of our use of a repeated 
measures regression analysis and adjusted for baseline characteristics, this increased SD 
probably reduced the statistical power of the trial.  Moreover, we tested multiple secondary and 
tertiary outcomes, although all were prespecified.  Strengths of the study include international 
recruitment in five countries and stable, modern glycaemic management, including insulin 
pump use by about a third of participants, increasing the generalisability of our findings. 
The results of REMOVAL do not support the assertion by current guidelines that metformin 
can improve glycaemic control in patients with type 1 diabetes, nor do they provide a rationale 
for restricting its use to those who are overweight or obese.   However, they do suggest that 
wider off-label use of metformin might be warranted to improve CVD risk management in type 
1 diabetes, and possibly also reduce insulin dose requirement.   
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Research in context  
Evidence before this study 
In our 2010 systematic review and meta-analysis, we captured all publications on type 1 
diabetes and metformin for any outcomes in PubMed (from Jan 1, 1950 to Oct 6, 2009) and 
EMBASE (Jan 1, 1974, to Oct 6, 2009) using medical search headings (MeSH): 1. ‘Diabetes 
Mellitus, Type 1’ [MeSH]; 2. (DIABET*) AND (TYPE 1 [TW] OR IDDM [TW]); OR 
(‘INSULIN DEPENDENT’ not ‘NON-INSULIN DEPENDENT’); 3. 1 OR 2; 4. ‘Metformin’ 
[MeSH]; 5. Metformin [TW]; 6. 4 OR 5.  The search was run by two independent researchers 
who manually searched publications and their citations and extracted data from all that were 
considered potentially relevant. Additionally, we searched for ongoing and unpublished trials in 
the following sources: Cochrane Library 2009 issue 1; Science Citation Index meeting abstracts 
1980–2008 (which includes the European Association for the Study of Diabetes and American 
Diabetes Association meetings 1980 to October 2008, Diabetes UK meeting abstracts 2002–08, 
and US Endocrine Society Abstracts 2005–08), the National Research Register,  and 
www.controlled-trials.com.  We identified only 192.8 participant-years of small, short term, 
and therefore low quality trials of metformin in patients with type 1 diabetes.  There was 
evidence for a reduction in insulin dose requirement by about 6.6 units per day (pooled 
estimate) when metformin was added to insulin treatment.  We noted bodyweight reduction 
with metformin in three of six studies and HbA1c reduction in four of seven studies but could 
not calculate pooled estimates because of heterogeneity.  Only the largest trial (n=100), in 
which only one third of participants were on statin therapy, showed lowering of LDL 
cholesterol with metformin.  Since our meta-analysis, several further small trials of metformin 
in type 1 diabetes have been reported, but also a larger (n=140), 6 month trial by the 
UST1DExchange in 140 overweight and obese adolescents. The results of the T1D Exchange 
trial showed bodyweight reduction with metformin, a similar reduction in insulin dose 
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requirement as in our systematic review, no reduction in LDL cholesterol, and improved 
glycaemic control at 3 months, but not at 6 months.  Despite the undoubted relevance of 
cardiovascular disease in patients with type 1 diabetes, no previous trials of any intervention 
have been done with either clinical or intermediate cardiovascular outcomes. 
Added value of this study 
REMOVAL, the largest and longest trial of metformin in type 1 diabetes to date, confirms 
favourable effects on bodyweight and supports previous evidence or reduced insulin dose 
requirement, as reported in our meta-analysis and more recently in the T1D Exchange Study. It 
is the first study to show a sustained reduction in LDL cholesterol in middle-aged individuals 
with type 1 diabetes treated to target with statin therapy. It is also the first to indicate a 
reduction in atherosclerosis progression with metformin in type 1 diabetes, based on a surrogate 
outcome of common carotid intima-media thickness,  although this finding was based on a 
tertiary rather than primary outcome.   
Implications of all the available evidence 
Our results provide a more rational basis for prescribing metformin, an inexpensive oral 
therapy, in patients with type 1 diabetes. Current guidelines in the UK and the USA 
recommend it for patients who are overweight or obese to reduce insulin dose requirement and 
improve glucose control.  We identified a transient improvement in glycaemia which reverted 
to baseline with insulin dose reduction and identified no suggestion of greater benefit in 
overweight or obese patients.  Type 1 diabetes guidelines should therefore be revised to reflect 
the absence of a sustained effect of adjunctive metformin on glycaemia and to remove the 
suggestion of particular efficacy in patients with a BMI greater than 25 kg/m
2
.  Since larger and 
longer trials to investigate the effect of metformin on clinical cardiovascular outcomes in type 1 
diabetes are unlikely to be done in the medium term, treatment decisions will have to be based 
on interpretation of the existing evidence.  Rather than a role in glycaemic control, our findings 
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suggest that long-term use of metformin in type 1 diabetes might reduce the long-term risk of 
cardiovascular disease via small but sustained reductions in bodyweight and LDL cholesterol.   
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Table 1: Baseline characteristics 
 
 Metformin 
(n=219) 
Placebo 
(n=209) 
Age (yrs) 55·2 (8·5) 55·8 (8·8) 
Male (%) 129 (59) 124 (59) 
White
1
 (%) 215 (98) 202 (97) 
Diabetes duration (years) 33·4 (11·0) 34·3 (10·5) 
C-peptide (nmol/L) 0·05 (0·03-0·10) 0·05 (0·03-0·10) 
Existing CVD (%) 
       MI or stroke  
       All
2 
  
 
17 (8) 
30 (14) 
 
12 (6) 
22 (11) 
Strong family history of 
CVD (%) 
60 (27) 54 (26) 
HbA1c  
     Absolute (mmol/mol) 
     Percentage units 
 
64·8 (9·4) 
8·1 (0·86) 
 
64·1 (8·5) 
8·0 (0·78) 
Insulin regimen (%)    
   Basal-bolus 
   Pump  
   Twice daily 
   Other 
 
128 (58) 
73 (33) 
5 (2) 
13 (6) 
 
122 (58) 
72 (34) 
7 (3) 
8 (4) 
Total daily insulin dose 
(units/kg) 
   Basal-bolus 
   Pump  
   Twice daily 
   Other 
   All 
 
 
0·67 (0·23) 
0·54 (0·29) 
0·73 (0·35) 
0·67 (0·23) 
0·63 (0·26) 
 
 
0.74 (0·29) 
0.57 (0·29) 
0.64 (0·27) 
0.73 (0·26) 
0·68 (0·30) 
BMI (kg/m
2
)  
BMI category (%) 
     Not Overweight 
     Overweight  
     Obese 
Unavailable 
28·4 (4·5) 
 
50 (23) 
103 (47) 
65 (30) 
1 
28·5 (4·1) 
 
44 (21) 
96 (46) 
69 (33) 
0 
Waist circumference (cm)  
      Men  
 
99·6 (11·6) 
 
100·0 (9·1) 
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      Women  92·1 (12·2) 91·5 (12·1) 
Systolic BP 
Diastolic BP (mmHg)  
130·5 (15·0) 
73·1 (9·9) 
128·5 (14·6) 
71·5 (10·3) 
Total cholesterol  
LDL cholesterol  
HDL cholesterol  
Triglycerides (mmol/L) 
4·0 (0·88) 
2·2 (0·70) 
1·6 (0·56) 
1·1 (0·77) 
4·0 (0·93) 
2·2 (0·72) 
1·6 (0·59) 
1·0 (0·57) 
Smoking history (%) 
     Current 
     Ex 
     Never 
 
35 (16) 
73 (33) 
111 (51) 
 
22 (11) 
71 (34) 
116 (56) 
eGFR (ml/min/1.73m
2
) 92·9 (20·9) 91·1 (21·6) 
Renal  (%) 
Normal 
(> 90 ml/min/1.73m
2
) 
Stage 1 CKD 
(> 90 ml/min/1.73m
2
) 
    Microalbuminuria 
    Proteinuria
3
 
Stage 2 CKD
4
 
  (60-89 ml/min/1.73m
2
) 
Stage 3a CKD
4
 
   (45-59 ml/min/1.73m
2
) 
 
 
128 (58) 
 
 
14 (6) 
11 (5) 
 
59 (27) 
 
7 (3) 
 
 
130 (62) 
 
 
14 (7) 
8 (4) 
 
48 (23) 
 
9 (4) 
Diabetic retinopathy
5
 
(%) 
None 
Non-proliferative 
Inactive proliferative 
Active proliferative 
Ungradable/ missing 
 
 
26 (12) 
140 (65) 
36 (17) 
15 (7) 
2 
 
 
16 (8) 
132 (64) 
39 (19) 
19 (9) 
3 
Neuropathy
6 
(%) 23 (11) 28 (13) 
Antihypertensives (%) 
Any 
 Angiotensin converting 
enzyme inhibitor 
 Angiotensin receptor 
     blocker 
 Calcium channel blocker 
 β-blocker 
 α-blocker 
 
156 (71) 
111 (51) 
 
43 (20) 
 
30 (14) 
19 (9) 
5 (2) 
 
157 (75) 
103 (49) 
 
49 (23) 
 
38 (18) 
19 (9) 
7 (3) 
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Statin 180 (82) 169 (81) 
Antiplatelet 
   Aspirin 
   Clopidogrel 
 
71 (32) 
10 (5) 
 
80 (38) 
6 (3) 
Mean(SD), median (range), or number (%).  Some percentages do not add up to 100% 
because of rounding. CVD = cardiovascular disease. MI = myocardial infarction. eGFR = 
estimated glomerular filtration rate. CKD=chronic kidney disease. *
1
self-report; 
2
includes 
heart failure, CABG, stent, angina, TIA, PVD; 
3
Macroalbuminuria; 
4
Micro- and 
proteinuria status not yet available for these CKD categories (as explained in Results); 
5
Modified Airlie House Classification (Worse eye); 
6
Impaired monofilament sensation 
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Table 2: Repeated measures analysis of common carotid artery intima-media thickness (cIMT) 
 
 
 Averaged mean far wall cIMT (mm) 
(primary outcome) 
Averaged maximal far wall cIMT (mm) 
(tertiary outcome) 
 Metformin Placebo Metformin Placebo 
Baseline 0·773 (0·140) 0·791 (0·183) 0·910 (0·162) 0·926 (0·225) 
12 months 0·782 (0·147) 0·788 (0·174) 0·920 (0·175) 0·939 (0·239) 
24 months 0·792 (0·145) 0·823 (0·187) 0·936 (0·161) 0·984 (0·251) 
36 months 0·793 (0·134) 0·820 (0·177) 0·949 (0·167) 0·999 (0·257) 
     
Main analysis
1
 
Slope (95% CI, mm/year) 0·006 (0·001, 0·011) 0·010 (0·006, 0·015) 0·012 (0·005, 0·019) 0·025 (0·018, 0·032) 
Difference in slope -0·005 (-0·012, 0·002); p=0.1664 -0·013 (-0·024, -0·003);  p=0·0093 
Data are mean (SD) unless otherwise indicated.  Analyses are for modified intention to treat of participants with at least one 
measurement after baseline.  cIMT=common carotid artery intima-media thickness. 
 
1
Adjusted for baseline age, sex, cIMT, smoking status, systolic BP, BMI, HbA1c, and LDL cholesterol 
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Table 3: Secondary outcomes  
 
 Baseline 36 months Change 
(ANCOVA)
 1
 
or OR 
(95% CIs)
 2
 
Main 
effect 
p 
Inter-
action
3
 
p 
 Metformin Placebo Metformin Placebo    
HbA1c (%) 8·1 (0·9) 8·0 (0·8) 8·1(0·9) 8·1(0·8) -0·13 
(-0·22, -0·04)
1
 
0·0060 0·0163 
LDL cholesterol 
(mmol/L) 
2·23 (0·70) 2·25 (0·72) 2·07 (0·83) 2·21 (0·71) -0·13 
(-0·24, -0·03)
 1
 
0·0117 0·3101 
eGFR (ml/min/ 1.73m2) 92·9 (20·9) 91·1 (21·6) 92·1 (20·8) 87·2 (19·6) 4·00 
(2·19, 5·81)
 1
 
<0·0001 0·6624 
Retinopathy (%) 
(≥ two-step progression) 
See Table 1 8 (6) 10 (8) 0·76 
(0·29, 1·98)
 2
 
0·5683 NA
4
 
Weight (kg) 83·9 (15·4) 83·5 (13·7) 82·0 (15·4)  83·2 (13·8) -1·17 
(-1·66, -0·69)
 1
 
<0·0001 0·2736 
Insulin dose (units/ kg) 0·63 (0·26) 0·68 (0·30) 0·62 (0·26) 0·67 (0·30) -0·005 
(-0·022, 0·012)
 1
 
0·5450 0·0018 
Endothelial function 
(RHI) (arbitrary units) 
2·28 (0·74) 2·24 (0·75) 2·17 (0·69) 2·24 (0·73) -0·06 
(-0·19, 0·06)
 1
 
 
0·3016 0·5662 
Data are mean (SD) for continuous data or n (%) for categorical data.  Treatment effect and corresponding 95% CIs are provided for metformin 
compared with placebo and are obtained by 
1
ANCOVA for the change from baseline, adjusted for the baseline value, for the continuous data.  
2
Odds 
Ratio (OR) and 95% CIs for binary data are obtained by logistic regression models.  
3
Visit-by-treatment interaction.  
4
Not applicable as assessed at 
only two visits (randomisation and close-out). 
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Table 4: Tertiary outcomes, adherence and safety 
 Baseline 36 months Change (ANCOVA)
 1
 
or HR
2
/IRR
3
 
(95% CI) 
p value 
 Metformi
n 
Placebo Metformin Placebo -  
 Tertiary outcomes       
    - Hypoglycaemia (per patient 
year) 
      
       Minor events 37·2 38·8 54·6 49·1 1·12 (0·92, 1.35)
 3
 0·2594 
       Major events 0·15 0·17 0·16 0·14 1·23 (0·73, 2·05)
 3
 0·4419 
    - Treatment satisfaction (units) 32·1 (3·6) 31·4 (4·2) 31·8 (4·2) 31·3 (4·8) -0·121 (-0·72, 0·47)
 1
 0·6880 
    - Vitamin B12 < 150 pmol/L(%)§ 0 0 24 (12) 9 (5) 2·76 (1·28, 5·95)
 2
 0·0094 
 Adherence and safety       
    - Treatment discontinuation 
(%) 
- - 59 (27) 26 (12) - 0·0002 
        Gastrointestinal - - 34 (16) 7 (3)   
            - nausea - - 20 (9) 5 (2) 
            - diarrhoea - - 18 (8) 3 (1) 
        Reduced eGFR  - - 0 0 
        Lactate  > 3·0 mmol/L (twice) 
                      > 5·0 mmol/L (any) 
- 
- 
- 
- 
1 (0·5) 
3 (1) 
0 (0) 
0 (0) 
    - Treatment downtitration (%) - - 67 (31) 18 (9) 
    - Study medication dose (mg/ 
day) 
- - 1434 (612) 1674 (343) 
    - Lactate (mmol/L) 1·31 
(0·76) 
1·23  (0·57) 1·30 (0·61) 1·19 (0·52) 0·078 (-0·032, 0·187)
 
1
 
0·1640 
Death 
       Cancer 
       Cardiac 
- 
- 
- 
- 
- 
- 
5 (2) 
3
4
 
2
6
 
2 (1) 
1
5
 
1
7
 
 
 
 
 
37 
 
Data are mean (SD) for continuous data or n (%) for categorical data.  Treatment effect and corresponding 95% Confidence Intervals (CIs) are provided for 
metformin compared with placebo.  eGFR=estimated glomerular filtration rate. 
1
ANCOVA for the change from baseline, adjusted for the baseline value for 
continuous data.  
2
Hazard Ratio (HR) and 95% CIs for time to first event data are obtained by Cox Proportional Hazards Model.   
3
Incidence Rate Ratio (IRR) 
and 95% CIs for count data are obtained by negative binomial regression models and including the logarithm of time as an offset.  The frequency of minor 
hypoglycaemia events is further adjusted for the method of collection. §Vitamin B12 data were missing for 25 people in the metformin group and 17 in the 
placebo group. 
4
Two non-small cell lung cancers, one malignant neoplasm of tongue; 
5
One glioblastoma; 
6
One myocardial infarction, one sudden death; 7 one myocardial 
infarction. 
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Figure Legends 
 
Figure 1: Trial profile 
cIMT=common carotid artery intima-media thickness. *One patient did not wish to proceed 
following a serious adverse event, one had a flare-up of irritable bowel syndrome, one 
withdrew because her husband became unwell, and one had a dislike of taking study 
medication. 
 
Figure 2: Progression in primary outcome (mean cIMT) (upper panel) and tertiary 
outcome (maximal cIMT) (lower panel) 
Error bars show 95% CIs, cIMT = common carotid artery intima-media thickness (far wall) 
 
Figure 3: Changes from baseline in secondary outcomes 
Mean change from baseline for up to three years is shown for HbA1c (upper left panel), 
insulin dose requirement (upper right panel), insulin dose requirement during first six months 
(middle left panel), LDL-cholesterol (middle right panel), weight (lower left panel), and 
eGFR (lower right panel).  Error bars show 95% CIs 
39 
 
Figure 1 
 
40 
 
Figure 2 
 
 
 
41 
 
Figure 3 
  
  
  
 
